Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer

FEBS Open Bio

  ^{1    1    1    1    1    1} 

[1] null;

关键词: Cervical cancer;    BIRC5;    MYC;    Autoantibodies;    ELISA;    Tumor immunity;   

DOI  :  10.1016/j.fob.2015.03.007

来源: publisher

【 摘 要 】

The present study was undertaken to detect circulating IgG antibodies to peptide antigens derived from baculoviral IAP repeat‐containing protein 5 isoform 2 (BIRC5) and myc proto‐oncogene protein (MYC) in cervical cancer. A total of 107 female patients with cervical cancer of stages I and II, and 130 healthy female subjects were recruited for analysis of circulating IgG antibodies to BIRC5 and MYC. Student'st‐test showed significant differences in circulating levels of anti‐BIRC5 IgG (t= −4.27, df = 235,P< 0.0001) and anti‐MYC IgG (t= 3.51, df = 232,P= 0.0005) between the patient group and the control group. Receiver operating characteristic (ROC) analysis showed an area under the ROC curve (AUC) of 0.67 with sensitivity of 23.4% against specificity of 90% for the anti‐BIRC5 IgG assay and an AUC of 0.66 with sensitivity of 9.4% against specificity of 90.6% for the anti‐MYC IgG assay. Analysis of quality control samples gave an inter‐assay deviation of 8.9% in the anti‐BIRC5 IgG assay and 9.0% in the anti‐MYC IgG assay. This work suggests that anti‐BIRC5 IgG could serve as a biomarker for early diagnosis of cervical cancer although a panel of such tumor‐associated antigens is needed to develop a highly sensitive test.

【 授权许可】

Unknown